secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zura Bio Ltd (ZURA)
CIK:        0001855644
Form:       8-K
Filed at:   2024-03-28T23:59:59+00:00
Accession:  0001104659-24-039882
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zura Bio reports FY2023 net loss $60.4M, cash $99.8M, appoints Robert Lisicki as CEO
--------------------------------------------------------------------------------

- Net loss of $60.4M for FY2023 vs $25.7M in FY2022; R&D expenses $44.0M, G&A $18.6M.
- Cash and equivalents of $99.8M as of Dec 31, 2023, expected to fund operations into 2026.
- Founder and CEO Someit Sidhu steps down; President Robert Lisicki appointed CEO effective April 8, 2024.
- Sidhu remains on board as non-independent director; Board expands to ten members.
- Plans to initiate Phase 2 trial of tibulizumab (ZB-106) for systemic sclerosis in 2H 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855644/000110465924039882/0001104659-24-039882-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855644/000110465924039882/tm2410061d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-039882

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer